Site Editor

Leo I. Gordon, MD, FACP

Advertisement
Advertisement

Utility of Routinely Collected Geriatric Assessment in Patients With DLBCL

By: Julia Fiederlein
Posted: Thursday, June 9, 2022

Adam J. Olszewski, MD, of the Alpert Medical School of Brown University, Providence, Rhode Island, and colleagues conducted a population-based study to determine whether data from the Outcome and Assessment Information Set (OASIS) may be used for pretreatment geriatric evaluation of older patients with diffuse large B-cell lymphoma (DLBCL). The results, which were published in JCO Oncology Practice, suggested an OASIS-based global risk indicator has the potential to guide chemotherapy and supportive care decisions in this population.

β€œIn our novel approach evaluating the association between OASIS assessments, cancer therapy, and patient outcomes, a global risk indicator integrating age, comorbidities, and functional and cognitive statuses was an independent predictor of treatment selection, short-term adverse events, and long-term overall survival in geriatric patients with diffuse large B-cell lymphoma,” the investigators commented. β€œ[It] was superior to assessments on the basis of single domains.”

Using data from the Surveillance, Epidemiology, and End Results (SEER)-Medicare database, the investigators identified 1,232 recipients of home care (median age, 80 years) diagnosed with DLBCL between 2011 and 2015 who had pretreatment OASIS evaluations. A global risk indicator categorizing patients as being at low, moderate, or high risk was created based on OASIS assessments.

A total of 65% of patients underwent chemotherapy. High-risk patients were less likely to undergo chemotherapy (odds ratio = 0.50) and curative regimens (odds ratio = 0.59); according to the investigators, 61% of moderate-risk patients received curative regimens. Acute mortality (odds ratio = 2.24), emergency department visits (odds ratio = 1.35), hospitalization (odds ratio = 1.60), and intensive care unit admission (odds ratio = 1.52) were more likely to occur in high-risk patients; this population was also found to experience inferior overall survival outcomes (hazard ratio = 1.41).

Disclosure: For full disclosures of the study authors, visit ascopubs.org.


By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.